In particular, Ki67 expression has been used as an index to classify patients with breast cancer into different risk categories and to guide adjuvant or neoadjuvant therapy (Aleskandarany et al. 2011; Chen et al. 2018; Petrelli et al. 2015). Here, MKI67 is linked to breast cancer.